Getinge

Q2 21: strong margins drive big earnings surprise

20/07/21 -"Getinge reported solid Q2 21 numbers. Sales were up 3.6% on an organic basis, driven by 36.5% growth in life science and 1.3% in acute care. As expected, the order book continued to decline (-6.1%) ..."

PDF page sample
Pages
62
Language
English
Published on
20/07/21
Download
You may also be interested by these reports :
09/11/26
Qiagen’s Q3 results exceeded management’s guidance, with sales primarily driven by Sample Technologies and Genomics/NGS. However, challenges in US ...
06/11/26
In early September 2026, we suggested that the 5 lean years for MedTechs performance had maybe reached an end. Bingo. The following chart confirms ...
06/11/26
S&N reported Q3 26 revenue of $1,551m (+3.4% organic), in line with consensus. Sports Medicine & ENT led (+7.9%), but continued weakness in US Knees ...
05/11/26
Siemens Healthineers’ Q4 profitability declined and was below market expectations. 2027 guidance also fell short of expectations. We will lower our ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO